Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

User Centered Reading Intervention for Individuals with Autism and Intellectual Disability.

Yakkundi A, Dillenburger K, Goodman L, Dounavi K.

Stud Health Technol Inform. 2017;242:249-256.

PMID:
28873806
2.

RALA-mediated delivery of FKBPL nucleic acid therapeutics.

Bennett R, Yakkundi A, McKeen HD, McClements L, McKeogh TJ, McCrudden CM, Arthur K, Robson T, McCarthy HO.

Nanomedicine (Lond). 2015 Oct;10(19):2989-3001. doi: 10.2217/nnm.15.115. Epub 2015 Sep 30.

3.

The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases.

McClements L, Annett S, Yakkundi A, Robson T.

Curr Mol Pharmacol. 2015;9(2):165-79.

PMID:
25986561
4.

FKBPL: a marker of good prognosis in breast cancer.

Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T.

Oncotarget. 2015 May 20;6(14):12209-23.

5.

FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.

Yakkundi A, Bennett R, Hernández-Negrete I, Delalande JM, Hanna M, Lyubomska O, Arthur K, Short A, McKeen H, Nelson L, McCrudden CM, McNally R, McClements L, McCarthy HO, Burns AJ, Bicknell R, Kissenpfennig A, Robson T.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):845-54. doi: 10.1161/ATVBAHA.114.304539. Epub 2015 Mar 12.

6.

Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.

Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A, Prise KM, McCarthy HO, Robson T.

Oncogene. 2014 Jun 26;33(26):3441-50. doi: 10.1038/onc.2013.306. Epub 2013 Aug 5.

PMID:
23912458
7.

Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.

McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T.

Clin Cancer Res. 2013 Jul 15;19(14):3881-93. doi: 10.1158/1078-0432.CCR-13-0595. Epub 2013 Jun 5.

8.

The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.

Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG, Robson T.

PLoS One. 2013;8(2):e55075. doi: 10.1371/journal.pone.0055075. Epub 2013 Feb 15.

9.

The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.

McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne C, Yakkundi A, McCarthy HO, Gallagher WM, Robson T.

Biochem Soc Trans. 2011 Apr;39(2):663-8. doi: 10.1042/BST0390663. Review.

PMID:
21428958
10.

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T.

Clin Cancer Res. 2011 Mar 1;17(5):1044-56. doi: 10.1158/1078-0432.CCR-10-2241. Epub 2011 Mar 1.

11.

FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.

McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, O'Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T.

Cancer Res. 2010 Feb 1;70(3):1090-100. doi: 10.1158/0008-5472.CAN-09-2515. Epub 2010 Jan 26.

12.

Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity.

Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, Johnston PG, Lappin TR.

Stem Cells. 2007 Mar;25(3):718-22. Epub 2006 Nov 16.

13.

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, Robson T.

Cancer Gene Ther. 2006 Jun;13(6):598-605.

PMID:
16410820
14.

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR.

J Gene Med. 2005 Jul;7(7):851-9.

PMID:
15712360
15.

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T.

Cancer Gene Ther. 2003 Jan;10(1):40-8.

PMID:
12489027

Supplemental Content

Loading ...
Support Center